Cite
Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease.
MLA
Lee, Nami, et al. “Hepatoprotective Effects of Gemigliptin and Empagliflozin in a Murine Model of Diet-Induced Non-Alcoholic Fatty Liver Disease.” Biochemical and Biophysical Research Communications, vol. 588, Jan. 2022, pp. 154–60. EBSCOhost, https://doi.org/10.1016/j.bbrc.2021.12.065.
APA
Lee, N., Heo, Y. J., Choi, S.-E., Jeon, J. Y., Han, S. J., Kim, D. J., Kang, Y., Lee, K. W., & Kim, H. J. (2022). Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease. Biochemical and Biophysical Research Communications, 588, 154–160. https://doi.org/10.1016/j.bbrc.2021.12.065
Chicago
Lee, Nami, Yu Jung Heo, Sung-E Choi, Ja Young Jeon, Seung Jin Han, Dae Jung Kim, Yup Kang, Kwan Woo Lee, and Hae Jin Kim. 2022. “Hepatoprotective Effects of Gemigliptin and Empagliflozin in a Murine Model of Diet-Induced Non-Alcoholic Fatty Liver Disease.” Biochemical and Biophysical Research Communications 588 (January): 154–60. doi:10.1016/j.bbrc.2021.12.065.